Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tara C Mitchell

Showing results (11-20 of 70) with videos related to

Pageof 7
Sort By:
Annals of Surgical Oncology|January 21, 2022
Adjuvant Nivolumab or Ipilimumab + Nivolumab for Melanoma Determined by Pathological Response to a Single Dose of Neoadjuvant NivolumabTahsin M Khan, Martha E Teke, Giorgos C Karakousis, et al.
Journal of Surgical Oncology|October 3, 2024
Sequencing of Immunotherapy and Outcomes in Operable Clinical Stage III Melanoma: A National Cohort StudyAnushka Dheer, Gabriella N Tortorello, Neha Shafique, et al.
JAMA Dermatology|July 21, 2018
Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor TherapyLeo L Wang, Gopal Patel, Zelma C Chiesa-Fuxench, et al.
Immunity|January 1, 2026
Immune signature-based uncoupling of checkpoint inhibitor efficacy and toxicityMinke W Lucas, Elizabeth M Burton, Petros Dimitriadis, et al.
Annals of Surgical Oncology|July 5, 2019
Survival Outcomes of Patients with Clinical Stage III Melanoma in the Era of Novel Systemic TherapiesYun Song, Andrew D Tieniber, Phyllis A Gimotty, et al.
Journal for Immunotherapy of Cancer|October 8, 2020
Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanomaJeffrey C Thompson, Christiana Davis, Charuhas Deshpande, et al.
The Oncologist|September 5, 2020
Impact of Tumor-Infiltrating Lymphocytes on Overall Survival in Merkel Cell CarcinomaAnish A Butala, Varsha Jain, Vishruth K Reddy, et al.
Journal of the American Academy of Dermatology|November 28, 2022
Sentinel lymph node biopsy status improves adjuvant therapy decision-making in patients with clinical stage IIB/C melanoma: A population-based analysisCimarron E Sharon, Richard J Straker, Phyllis A Gimotty, et al.
Annals of Surgical Oncology|January 4, 2020
Neoadjuvant Versus Adjuvant Immune Checkpoint Blockade in the Treatment of Clinical Stage III MelanomaYun Song, Richard J Straker, Xiaowei Xu, et al.
American Journal of Ophthalmology Case Reports|August 7, 2024
<i>Anti</i>-TRPM1 autoantibody-positive unilateral melanoma associated retinopathy (MAR) triggered by immunotherapy recapitulates functional and structural details of <i>TRPM1</i>-associated congenital stationary night blindnessDevin C Cohen, Alexander Sumaroka, Joshua A Paulos, et al.
Pageof 7

Showing results (11-20 of 70) with videos related to

Sort By:
Pageof 7
Annals of Surgical Oncology|January 21, 2022
Adjuvant Nivolumab or Ipilimumab + Nivolumab for Melanoma Determined by Pathological Response to a Single Dose of Neoadjuvant NivolumabTahsin M Khan, Martha E Teke, Giorgos C Karakousis, et al.
Journal of Surgical Oncology|October 3, 2024
Sequencing of Immunotherapy and Outcomes in Operable Clinical Stage III Melanoma: A National Cohort StudyAnushka Dheer, Gabriella N Tortorello, Neha Shafique, et al.
JAMA Dermatology|July 21, 2018
Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor TherapyLeo L Wang, Gopal Patel, Zelma C Chiesa-Fuxench, et al.
Immunity|January 1, 2026
Immune signature-based uncoupling of checkpoint inhibitor efficacy and toxicityMinke W Lucas, Elizabeth M Burton, Petros Dimitriadis, et al.
Annals of Surgical Oncology|July 5, 2019
Survival Outcomes of Patients with Clinical Stage III Melanoma in the Era of Novel Systemic TherapiesYun Song, Andrew D Tieniber, Phyllis A Gimotty, et al.
Journal for Immunotherapy of Cancer|October 8, 2020
Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanomaJeffrey C Thompson, Christiana Davis, Charuhas Deshpande, et al.
The Oncologist|September 5, 2020
Impact of Tumor-Infiltrating Lymphocytes on Overall Survival in Merkel Cell CarcinomaAnish A Butala, Varsha Jain, Vishruth K Reddy, et al.
Journal of the American Academy of Dermatology|November 28, 2022
Sentinel lymph node biopsy status improves adjuvant therapy decision-making in patients with clinical stage IIB/C melanoma: A population-based analysisCimarron E Sharon, Richard J Straker, Phyllis A Gimotty, et al.
Annals of Surgical Oncology|January 4, 2020
Neoadjuvant Versus Adjuvant Immune Checkpoint Blockade in the Treatment of Clinical Stage III MelanomaYun Song, Richard J Straker, Xiaowei Xu, et al.
American Journal of Ophthalmology Case Reports|August 7, 2024
<i>Anti</i>-TRPM1 autoantibody-positive unilateral melanoma associated retinopathy (MAR) triggered by immunotherapy recapitulates functional and structural details of <i>TRPM1</i>-associated congenital stationary night blindnessDevin C Cohen, Alexander Sumaroka, Joshua A Paulos, et al.
Pageof 7